VISEN Pharmaceuticals
Company Profile
Business description
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
Contact
69 Jiuzhang Road
Suite 3-108, Floor 3, Building B
Hengtai Lixiang Chuangxin Tower
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
52
Stocks News & Analysis
stocks
Our three most overvalued ASX shares
stocks
What does big US court decision mean for Google’s parent company Alphabet?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,126.90 | 2.50 | -0.03% |
CAC 40 | 7,720.44 | 21.52 | 0.28% |
DAX 40 | 23,702.04 | 105.06 | 0.45% |
Dow JONES (US) | 45,316.53 | 304.76 | -0.67% |
FTSE 100 | 9,227.04 | 18.83 | 0.20% |
HKSE | 25,633.91 | 215.93 | 0.85% |
NASDAQ | 21,700.39 | 7.30 | -0.03% |
Nikkei 225 | 43,643.81 | 625.06 | 1.45% |
NZX 50 Index | 13,281.14 | 57.61 | 0.44% |
S&P 500 | 6,464.58 | 16.92 | -0.26% |
S&P/ASX 200 | 8,849.60 | 5.60 | -0.06% |
SSE Composite Index | 3,826.84 | 14.33 | 0.38% |